<?xml version='1.0' encoding='utf-8'?>
<document id="15963007"><sentence text="Drug interactions of clinical importance with antihyperglycaemic agents: an update." /><sentence text="Because management of type 2 diabetes mellitus usually involves combined pharmacological therapy to obtain adequate glucose control and treatment of concurrent pathologies (especially dyslipidaemia and arterial hypertension), drug-drug interactions must be carefully considered with antihyperglycaemic drugs"><entity charOffset="116-123" id="DDI-PubMed.15963007.s2.e0" text="glucose" /></sentence><sentence text=" Additive glucose-lowering effects have been extensively reported when combining sulphonylureas (or the new insulin secretagogues, meglitinide derivatives, i"><entity charOffset="10-17" id="DDI-PubMed.15963007.s3.e0" text="glucose" /><entity charOffset="81-95" id="DDI-PubMed.15963007.s3.e1" text="sulphonylureas" /><entity charOffset="131-142" id="DDI-PubMed.15963007.s3.e2" text="meglitinide" /><pair ddi="false" e1="DDI-PubMed.15963007.s3.e0" e2="DDI-PubMed.15963007.s3.e0" /><pair ddi="false" e1="DDI-PubMed.15963007.s3.e0" e2="DDI-PubMed.15963007.s3.e1" /><pair ddi="false" e1="DDI-PubMed.15963007.s3.e0" e2="DDI-PubMed.15963007.s3.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s3.e1" e2="DDI-PubMed.15963007.s3.e1" /><pair ddi="false" e1="DDI-PubMed.15963007.s3.e1" e2="DDI-PubMed.15963007.s3.e2" /></sentence><sentence text="e" /><sentence text=" nateglinide and repaglinide) with metformin, sulphonylureas (or meglitinide derivatives) with thiazolidinediones (also called glitazones) and the biguanide compound metformin with thiazolidinediones"><entity charOffset="1-12" id="DDI-PubMed.15963007.s5.e0" text="nateglinide" /><entity charOffset="17-28" id="DDI-PubMed.15963007.s5.e1" text="repaglinide" /><entity charOffset="35-44" id="DDI-PubMed.15963007.s5.e2" text="metformin" /><entity charOffset="46-60" id="DDI-PubMed.15963007.s5.e3" text="sulphonylureas" /><entity charOffset="65-76" id="DDI-PubMed.15963007.s5.e4" text="meglitinide" /><entity charOffset="95-113" id="DDI-PubMed.15963007.s5.e5" text="thiazolidinediones" /><entity charOffset="127-137" id="DDI-PubMed.15963007.s5.e6" text="glitazones" /><entity charOffset="147-156" id="DDI-PubMed.15963007.s5.e7" text="biguanide" /><entity charOffset="166-175" id="DDI-PubMed.15963007.s5.e8" text="metformin" /><entity charOffset="181-199" id="DDI-PubMed.15963007.s5.e9" text="thiazolidinediones" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e0" e2="DDI-PubMed.15963007.s5.e0" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e0" e2="DDI-PubMed.15963007.s5.e1" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e0" e2="DDI-PubMed.15963007.s5.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e0" e2="DDI-PubMed.15963007.s5.e3" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e0" e2="DDI-PubMed.15963007.s5.e4" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e0" e2="DDI-PubMed.15963007.s5.e5" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e0" e2="DDI-PubMed.15963007.s5.e6" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e0" e2="DDI-PubMed.15963007.s5.e7" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e0" e2="DDI-PubMed.15963007.s5.e8" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e0" e2="DDI-PubMed.15963007.s5.e9" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e1" e2="DDI-PubMed.15963007.s5.e1" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e1" e2="DDI-PubMed.15963007.s5.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e1" e2="DDI-PubMed.15963007.s5.e3" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e1" e2="DDI-PubMed.15963007.s5.e4" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e1" e2="DDI-PubMed.15963007.s5.e5" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e1" e2="DDI-PubMed.15963007.s5.e6" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e1" e2="DDI-PubMed.15963007.s5.e7" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e1" e2="DDI-PubMed.15963007.s5.e8" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e1" e2="DDI-PubMed.15963007.s5.e9" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e2" e2="DDI-PubMed.15963007.s5.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e2" e2="DDI-PubMed.15963007.s5.e3" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e2" e2="DDI-PubMed.15963007.s5.e4" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e2" e2="DDI-PubMed.15963007.s5.e5" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e2" e2="DDI-PubMed.15963007.s5.e6" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e2" e2="DDI-PubMed.15963007.s5.e7" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e2" e2="DDI-PubMed.15963007.s5.e8" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e2" e2="DDI-PubMed.15963007.s5.e9" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e3" e2="DDI-PubMed.15963007.s5.e3" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e3" e2="DDI-PubMed.15963007.s5.e4" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e3" e2="DDI-PubMed.15963007.s5.e5" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e3" e2="DDI-PubMed.15963007.s5.e6" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e3" e2="DDI-PubMed.15963007.s5.e7" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e3" e2="DDI-PubMed.15963007.s5.e8" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e3" e2="DDI-PubMed.15963007.s5.e9" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e4" e2="DDI-PubMed.15963007.s5.e4" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e4" e2="DDI-PubMed.15963007.s5.e5" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e4" e2="DDI-PubMed.15963007.s5.e6" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e4" e2="DDI-PubMed.15963007.s5.e7" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e4" e2="DDI-PubMed.15963007.s5.e8" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e4" e2="DDI-PubMed.15963007.s5.e9" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e5" e2="DDI-PubMed.15963007.s5.e5" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e5" e2="DDI-PubMed.15963007.s5.e6" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e5" e2="DDI-PubMed.15963007.s5.e7" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e5" e2="DDI-PubMed.15963007.s5.e8" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e5" e2="DDI-PubMed.15963007.s5.e9" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e6" e2="DDI-PubMed.15963007.s5.e6" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e6" e2="DDI-PubMed.15963007.s5.e7" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e6" e2="DDI-PubMed.15963007.s5.e8" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e6" e2="DDI-PubMed.15963007.s5.e9" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e7" e2="DDI-PubMed.15963007.s5.e7" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e7" e2="DDI-PubMed.15963007.s5.e8" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e7" e2="DDI-PubMed.15963007.s5.e9" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e8" e2="DDI-PubMed.15963007.s5.e8" /><pair ddi="false" e1="DDI-PubMed.15963007.s5.e8" e2="DDI-PubMed.15963007.s5.e9" /></sentence><sentence text=" Interest in combining alpha-glucosidase inhibitors with either sulphonylureas (or meglitinide derivatives), metformin or thiazolidinediones has also been demonstrated"><entity charOffset="64-78" id="DDI-PubMed.15963007.s6.e0" text="sulphonylureas" /><entity charOffset="83-94" id="DDI-PubMed.15963007.s6.e1" text="meglitinide" /><entity charOffset="109-118" id="DDI-PubMed.15963007.s6.e2" text="metformin" /><entity charOffset="122-140" id="DDI-PubMed.15963007.s6.e3" text="thiazolidinediones" /><pair ddi="false" e1="DDI-PubMed.15963007.s6.e0" e2="DDI-PubMed.15963007.s6.e0" /><pair ddi="false" e1="DDI-PubMed.15963007.s6.e0" e2="DDI-PubMed.15963007.s6.e1" /><pair ddi="false" e1="DDI-PubMed.15963007.s6.e0" e2="DDI-PubMed.15963007.s6.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s6.e0" e2="DDI-PubMed.15963007.s6.e3" /><pair ddi="false" e1="DDI-PubMed.15963007.s6.e1" e2="DDI-PubMed.15963007.s6.e1" /><pair ddi="false" e1="DDI-PubMed.15963007.s6.e1" e2="DDI-PubMed.15963007.s6.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s6.e1" e2="DDI-PubMed.15963007.s6.e3" /><pair ddi="false" e1="DDI-PubMed.15963007.s6.e2" e2="DDI-PubMed.15963007.s6.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s6.e2" e2="DDI-PubMed.15963007.s6.e3" /></sentence><sentence text=" These combinations result in lower glycosylated haemoglobin (HbA(1c)), fasting glucose and postprandial glucose levels than with either monotherapy"><entity charOffset="80-87" id="DDI-PubMed.15963007.s7.e0" text="glucose" /><entity charOffset="105-112" id="DDI-PubMed.15963007.s7.e1" text="glucose" /><pair ddi="false" e1="DDI-PubMed.15963007.s7.e0" e2="DDI-PubMed.15963007.s7.e0" /><pair ddi="false" e1="DDI-PubMed.15963007.s7.e0" e2="DDI-PubMed.15963007.s7.e1" /></sentence><sentence text=" Even if modest pharmacokinetic interferences have been reported with some combinations, they do not appear to have important clinical consequences" /><sentence text=" No significant adverse effects, except a higher risk of hypoglycaemic episodes that may be attributed to better glycaemic control, occur with any combination" /><sentence text=" Challenging the classical dual therapy with sulphonylurea plus metformin, there is a recent trend to use alternative dual combinations (sulphonylurea plus thiazolidinedione or metformin plus thiazolidinedione)"><entity charOffset="137-150" id="DDI-PubMed.15963007.s10.e0" text="sulphonylurea" /><entity charOffset="156-173" id="DDI-PubMed.15963007.s10.e1" text="thiazolidinedione" /><entity charOffset="177-186" id="DDI-PubMed.15963007.s10.e2" text="metformin" /><entity charOffset="192-209" id="DDI-PubMed.15963007.s10.e3" text="thiazolidinedione" /><pair ddi="false" e1="DDI-PubMed.15963007.s10.e0" e2="DDI-PubMed.15963007.s10.e0" /><pair ddi="false" e1="DDI-PubMed.15963007.s10.e0" e2="DDI-PubMed.15963007.s10.e1" /><pair ddi="false" e1="DDI-PubMed.15963007.s10.e0" e2="DDI-PubMed.15963007.s10.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s10.e0" e2="DDI-PubMed.15963007.s10.e3" /><pair ddi="false" e1="DDI-PubMed.15963007.s10.e1" e2="DDI-PubMed.15963007.s10.e1" /><pair ddi="false" e1="DDI-PubMed.15963007.s10.e1" e2="DDI-PubMed.15963007.s10.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s10.e1" e2="DDI-PubMed.15963007.s10.e3" /><pair ddi="false" e1="DDI-PubMed.15963007.s10.e2" e2="DDI-PubMed.15963007.s10.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s10.e2" e2="DDI-PubMed.15963007.s10.e3" /></sentence><sentence text=" In addition, triple therapy with the addition of a thiazolidinedione to the metformin-sulphonylurea combination has been recently evaluated and allows glucose targets to be reached before insulin therapy is considered"><entity charOffset="52-69" id="DDI-PubMed.15963007.s11.e0" text="thiazolidinedione" /><entity charOffset="77-86" id="DDI-PubMed.15963007.s11.e1" text="metformin" /><entity charOffset="87-100" id="DDI-PubMed.15963007.s11.e2" text="sulphonylurea" /><entity charOffset="152-159" id="DDI-PubMed.15963007.s11.e3" text="glucose" /><pair ddi="false" e1="DDI-PubMed.15963007.s11.e0" e2="DDI-PubMed.15963007.s11.e0" /><pair ddi="false" e1="DDI-PubMed.15963007.s11.e0" e2="DDI-PubMed.15963007.s11.e1" /><pair ddi="false" e1="DDI-PubMed.15963007.s11.e0" e2="DDI-PubMed.15963007.s11.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s11.e0" e2="DDI-PubMed.15963007.s11.e3" /><pair ddi="false" e1="DDI-PubMed.15963007.s11.e1" e2="DDI-PubMed.15963007.s11.e1" /><pair ddi="false" e1="DDI-PubMed.15963007.s11.e1" e2="DDI-PubMed.15963007.s11.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s11.e1" e2="DDI-PubMed.15963007.s11.e3" /><pair ddi="false" e1="DDI-PubMed.15963007.s11.e2" e2="DDI-PubMed.15963007.s11.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s11.e2" e2="DDI-PubMed.15963007.s11.e3" /></sentence><sentence text=" This triple therapy appears to be safe, with no deleterious drug-drug interactions being reported so far" /><sentence text="Potential interferences may also occur between glucose-lowering agents and other drugs, and such drug-drug interactions may have important clinical implications"><entity charOffset="47-54" id="DDI-PubMed.15963007.s13.e0" text="glucose" /></sentence><sentence text=" Relevant pharmacological agents are those that are widely coadministered in diabetic patients (e" /><sentence text="g" /><sentence text=" lipid-lowering agents, antihypertensive agents); those that have a narrow efficacy/toxicity ratio (e" /><sentence text="g" /><sentence text=" digoxin, warfarin); or those that are known to induce (rifampicin [rifampin]) or inhibit (fluconazole) the cytochrome P450 (CYP) system"><entity charOffset="1-8" id="DDI-PubMed.15963007.s18.e0" text="digoxin" /><entity charOffset="10-18" id="DDI-PubMed.15963007.s18.e1" text="warfarin" /><entity charOffset="56-66" id="DDI-PubMed.15963007.s18.e2" text="rifampicin" /><entity charOffset="91-102" id="DDI-PubMed.15963007.s18.e3" text="fluconazole" /><pair ddi="false" e1="DDI-PubMed.15963007.s18.e0" e2="DDI-PubMed.15963007.s18.e0" /><pair ddi="false" e1="DDI-PubMed.15963007.s18.e0" e2="DDI-PubMed.15963007.s18.e1" /><pair ddi="false" e1="DDI-PubMed.15963007.s18.e0" e2="DDI-PubMed.15963007.s18.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s18.e0" e2="DDI-PubMed.15963007.s18.e3" /><pair ddi="false" e1="DDI-PubMed.15963007.s18.e1" e2="DDI-PubMed.15963007.s18.e1" /><pair ddi="false" e1="DDI-PubMed.15963007.s18.e1" e2="DDI-PubMed.15963007.s18.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s18.e1" e2="DDI-PubMed.15963007.s18.e3" /><pair ddi="false" e1="DDI-PubMed.15963007.s18.e2" e2="DDI-PubMed.15963007.s18.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s18.e2" e2="DDI-PubMed.15963007.s18.e3" /></sentence><sentence text=" Metformin is currently a key compound in the pharmacological management of type 2 diabetes, used either alone or in combination with other antihyperglycaemics"><entity charOffset="1-10" id="DDI-PubMed.15963007.s19.e0" text="Metformin" /></sentence><sentence text=" There are no clinically relevant metabolic interactions with metformin, because this compound is not metabolised and does not inhibit the metabolism of other drugs"><entity charOffset="62-71" id="DDI-PubMed.15963007.s20.e0" text="metformin" /></sentence><sentence text=" In contrast, sulphonylureas, meglitinide derivatives and thiazolidinediones are extensively metabolised in the liver via the CYP system and thus, may be subject to drug-drug metabolic interactions"><entity charOffset="14-28" id="DDI-PubMed.15963007.s21.e0" text="sulphonylureas" /><entity charOffset="30-41" id="DDI-PubMed.15963007.s21.e1" text="meglitinide" /><entity charOffset="58-76" id="DDI-PubMed.15963007.s21.e2" text="thiazolidinediones" /><pair ddi="false" e1="DDI-PubMed.15963007.s21.e0" e2="DDI-PubMed.15963007.s21.e0" /><pair ddi="false" e1="DDI-PubMed.15963007.s21.e0" e2="DDI-PubMed.15963007.s21.e1" /><pair ddi="false" e1="DDI-PubMed.15963007.s21.e0" e2="DDI-PubMed.15963007.s21.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s21.e1" e2="DDI-PubMed.15963007.s21.e1" /><pair ddi="false" e1="DDI-PubMed.15963007.s21.e1" e2="DDI-PubMed.15963007.s21.e2" /></sentence><sentence text=" Many HMG-CoA reductase inhibitors (statins) are also metabolised via the CYP system" /><sentence text=" Even if modest pharmacokinetic interactions may occur, it is not clear whether drug-drug interactions between oral antihyperglycaemic agents and statins may have clinical consequences regarding both efficacy and safety" /><sentence text=" In contrast, a marked pharmacokinetic interference has been reported between gemfibrozil and repaglinide and, to a lesser extent, between gemfibrozil and rosiglitazone"><entity charOffset="78-89" id="DDI-PubMed.15963007.s24.e0" text="gemfibrozil" /><entity charOffset="94-105" id="DDI-PubMed.15963007.s24.e1" text="repaglinide" /><entity charOffset="139-150" id="DDI-PubMed.15963007.s24.e2" text="gemfibrozil" /><entity charOffset="155-168" id="DDI-PubMed.15963007.s24.e3" text="rosiglitazone" /><pair ddi="false" e1="DDI-PubMed.15963007.s24.e0" e2="DDI-PubMed.15963007.s24.e0" /><pair ddi="false" e1="DDI-PubMed.15963007.s24.e0" e2="DDI-PubMed.15963007.s24.e1" /><pair ddi="false" e1="DDI-PubMed.15963007.s24.e0" e2="DDI-PubMed.15963007.s24.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s24.e0" e2="DDI-PubMed.15963007.s24.e3" /><pair ddi="false" e1="DDI-PubMed.15963007.s24.e1" e2="DDI-PubMed.15963007.s24.e1" /><pair ddi="false" e1="DDI-PubMed.15963007.s24.e1" e2="DDI-PubMed.15963007.s24.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s24.e1" e2="DDI-PubMed.15963007.s24.e3" /><pair ddi="false" e1="DDI-PubMed.15963007.s24.e2" e2="DDI-PubMed.15963007.s24.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s24.e2" e2="DDI-PubMed.15963007.s24.e3" /></sentence><sentence text=" This leads to a drastic increase in plasma concentrations of each antihyperglycaemic agent when they are coadministered with the fibric acid derivative, and an increased risk of adverse effects"><entity charOffset="130-141" id="DDI-PubMed.15963007.s25.e0" text="fibric acid" /></sentence><sentence text=" Some antihypertensive agents may favour hypoglycaemic episodes when co-prescribed with sulphonylureas or meglitinide derivatives, especially ACE inhibitors, but this effect seems to result from a pharmacodynamic drug-drug interaction rather than from a pharmacokinetic drug-drug interaction"><entity charOffset="88-102" id="DDI-PubMed.15963007.s26.e0" text="sulphonylureas" /><entity charOffset="106-117" id="DDI-PubMed.15963007.s26.e1" text="meglitinide" /><pair ddi="false" e1="DDI-PubMed.15963007.s26.e0" e2="DDI-PubMed.15963007.s26.e0" /><pair ddi="false" e1="DDI-PubMed.15963007.s26.e0" e2="DDI-PubMed.15963007.s26.e1" /></sentence><sentence text=" No, or only modest, interferences have been described with glucose-lowering agents and other pharmacological compounds such as digoxin or warfarin"><entity charOffset="1-3" id="DDI-PubMed.15963007.s27.e0" text="No" /><entity charOffset="60-67" id="DDI-PubMed.15963007.s27.e1" text="glucose" /><entity charOffset="128-135" id="DDI-PubMed.15963007.s27.e2" text="digoxin" /><entity charOffset="139-147" id="DDI-PubMed.15963007.s27.e3" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.15963007.s27.e0" e2="DDI-PubMed.15963007.s27.e0" /><pair ddi="false" e1="DDI-PubMed.15963007.s27.e0" e2="DDI-PubMed.15963007.s27.e1" /><pair ddi="false" e1="DDI-PubMed.15963007.s27.e0" e2="DDI-PubMed.15963007.s27.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s27.e0" e2="DDI-PubMed.15963007.s27.e3" /><pair ddi="false" e1="DDI-PubMed.15963007.s27.e1" e2="DDI-PubMed.15963007.s27.e1" /><pair ddi="false" e1="DDI-PubMed.15963007.s27.e1" e2="DDI-PubMed.15963007.s27.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s27.e1" e2="DDI-PubMed.15963007.s27.e3" /><pair ddi="false" e1="DDI-PubMed.15963007.s27.e2" e2="DDI-PubMed.15963007.s27.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s27.e2" e2="DDI-PubMed.15963007.s27.e3" /></sentence><sentence text=" The effects of inducers or inhibitors of CYP isoenzymes on the metabolism and pharmacokinetics of the glucose-lowering agents of each pharmacological class has been tested"><entity charOffset="103-110" id="DDI-PubMed.15963007.s28.e0" text="glucose" /></sentence><sentence text=" Significantly increased (with CYP inhibitors) or decreased (with CYP inducers) plasma levels of sulphonylureas, meglitinide derivatives and thiazolidinediones have been reported in healthy volunteers, and these pharmacokinetic changes may lead to enhanced or reduced glucose-lowering action, and thus hypoglycaemia or worsening of metabolic control, respectively"><entity charOffset="97-111" id="DDI-PubMed.15963007.s29.e0" text="sulphonylureas" /><entity charOffset="113-124" id="DDI-PubMed.15963007.s29.e1" text="meglitinide" /><entity charOffset="141-159" id="DDI-PubMed.15963007.s29.e2" text="thiazolidinediones" /><entity charOffset="268-275" id="DDI-PubMed.15963007.s29.e3" text="glucose" /><pair ddi="false" e1="DDI-PubMed.15963007.s29.e0" e2="DDI-PubMed.15963007.s29.e0" /><pair ddi="false" e1="DDI-PubMed.15963007.s29.e0" e2="DDI-PubMed.15963007.s29.e1" /><pair ddi="false" e1="DDI-PubMed.15963007.s29.e0" e2="DDI-PubMed.15963007.s29.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s29.e0" e2="DDI-PubMed.15963007.s29.e3" /><pair ddi="false" e1="DDI-PubMed.15963007.s29.e1" e2="DDI-PubMed.15963007.s29.e1" /><pair ddi="false" e1="DDI-PubMed.15963007.s29.e1" e2="DDI-PubMed.15963007.s29.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s29.e1" e2="DDI-PubMed.15963007.s29.e3" /><pair ddi="false" e1="DDI-PubMed.15963007.s29.e2" e2="DDI-PubMed.15963007.s29.e2" /><pair ddi="false" e1="DDI-PubMed.15963007.s29.e2" e2="DDI-PubMed.15963007.s29.e3" /></sentence><sentence text=" In addition, some case reports have evidenced potential drug-drug interactions with various antihyperglycaemic agents that are usually associated with a higher risk of hypoglycaemia" /><sentence text="" /></document>